$PBIO Characterization of Specific Cancers Using P
Post# of 47038
Several presentations illustrated the flexibility of PCT to extract proteins and nucleic acids from different types of tissue biopsies used in the characterization of specific cancers.
Data presented from a study conducted by 12 scientists from four leading academic and research institutions in China demonstrated the effectiveness and practicality of PCT in a study of colorectal cancer.
Another study showed PCT to be an effective component of the workflow to help highlight details of gastric cancer, including key information that could aid in the discovery of novel prognostic markers and potential therapeutic targets.
Yet another cancer-related study showed that the combination of PCT and mass spectrometry could result in a superior method for “ruling-in and ruling-out” cancer in thyroid nodules compared to current diagnostic tests.
Dr. Nate Lawrence, Senior Consultant to PBI, said: “We are excited that international teams of scientists from more than seventeen institutions on four continents contributed to presentations showing the power and versatility of PCT for cancer research, biomarker discovery, proteomics, and molecular biology. It has been projected that these combined markets are expected to be in excess of $200 billion by 2025 (Zion Market Research, 2019).”
In summation, Ms. McCloskey commented: “We believe the unique value provided by our PCT platform for cancer research and diagnostics, which was broadly highlighted across ten presentations at this important international human protein conference, will help to accelerate awareness and adoption for our unique PCT sample preparation platform across multiple large and growing markets. Subsequently, we believe this increased awareness and conversion into adoption will result in increased sales of our PCT instruments and consumables in Q4 2019 and beyond."
https://www.barchart.com/story/stocks/quotes/...conference